Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Impact · against what's priced in

Elutia receives a modest cash infusion of $8 million with potential for $3 million more, though the scale is small relative to typical biotech market caps. The deal represents a successful divestiture of the SimpliDerm business, shifting risk to Cellution Biologics.

ELUT+0.20

No priced-in read yet

In context

The company has completed the sale of its SimpliDerm business for an initial $8 million payment, with up to $3 million in additional milestone payments possible over 18 months.

Read from the article alone

• m and a▲11%
• healthcare
• ELUT
• acquisition
• biologics
• biotechnology
• medical devices
• reconstructive surgery
• tissue engineering